Navigation Links
Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Date:8/30/2007

SAN DIEGO, Aug. 30 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced it has completed patient enrollment in a pivotal Phase III clinical trial to evaluate its investigational product candidate, intravenous acetaminophen (IV acetaminophen), for the treatment of acute pain following gynecologic surgery. This clinical trial is part of a comprehensive Phase III clinical development program for IV acetaminophen, which includes pivotal efficacy studies for the treatment of acute pain and fever, as well as safety and pharmacokinetic studies.

"The completion of patient enrollment in this clinical trial is an important milestone for Cadence," said Ted Schroeder, President and Chief Executive Officer of Cadence. "We believe that intravenous acetaminophen has the potential to meet a significant unmet medical need for an effective intravenous analgesic to treat acute pain and fever without the unwanted side effects associated with currently available treatments."

Cadence's pivotal trial of IV acetaminophen for the treatment of pain following gynecologic surgery, referred to as the IV APAP 301 Study, is a randomized, double-blind, placebo-controlled study in which a total of 331 subjects have been enrolled at 27 sites throughout the United States. Patients were treated with either IV acetaminophen or placebo in the 48-hour period following gynecologic surgery. The primary endpoint of the trial is analgesic efficacy, measured by reduction in pain intensity, compared to placebo.

"The IV APAP 301 Study is a critical eleme
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... KING OF PRUSSIA, Pa. , Feb. 27, 2015 ... part of its ongoing commitment to the global bleeding ... it is donating 2 million international units (IUs) of ... WFH is an international not-for- profit organization which has ... and other inherited bleeding disorders. The donation supports the ...
(Date:2/27/2015)... TEL-AVIV, Israel , February 27, 2015 ... Unternehmen baut sein bahnbrechendes Überwachungssystem für kongestive ... weiter aus -   ... Medical Technologies, die ein neuartiges Herzüberwachungssystem für ... gab heute bekannt, dass sie ein Finanzierungsvorhaben ...
(Date:2/27/2015)... 2015  Two mass spectrometry technologies MALDI ... their effectiveness is established, according to biotechnology ... says that while mass spectrometry (mass spec ... in proteomic biomarker discovery and validation, mass ... techniques has struggled to elucidate molecular distribution ...
Breaking Medicine Technology:CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 3Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3
... Mich., Jan. 23, 2012  Researchers at the University of ... and found that less expensive, more effective tests are ... of patients receiving neuropathy diagnoses undergo high-cost, low-yield MRIs ... according to the study that will be published Jan. ...
... FALLS, N.Y., Jan. 23, 2012  Niagara Thermal Products LLC ... & Sons, Inc. The acquisition brings together two highly ... value custom thermal solutions in the aerospace, defense and ... ) "The addition of Kittredge,s industry recognized ...
Cached Medicine Technology:Neuropathy Patients More Likely to Receive High-cost, Low-yield Screening Instead of More Effective Tests 2Neuropathy Patients More Likely to Receive High-cost, Low-yield Screening Instead of More Effective Tests 3Niagara Thermal Products LLC Announces the Acquisition of J. Kittredge & Sons, Inc. 2Niagara Thermal Products LLC Announces the Acquisition of J. Kittredge & Sons, Inc. 3
(Date:2/28/2015)... February 28, 2015 The noted Friedman ... that they have officially relaunched their website. The new ... but it contains a new section about their team ... read the full biographies of each Friedman Dental Group ... the website was designed to provide our patients with ...
(Date:2/28/2015)... Javon Bea Mercy Health System CEO ... stroke capable by the State of Illinois, enabling potential ... Harvard Hospital. , The hospital was required to submit ... treat stroke according to national standards of care for ... to bypass hospitals not designated as an Emergent Stroke ...
(Date:2/28/2015)... Memphis, TN: MedixSafe has retracted a previous ... security reader named Guardian 2. The correct product ... biometric scanner that significantly increases the complexity of ... biometric scanner provides fast and easy access for ... narcotics lockers with Vanguard technology tracks inventory ...
(Date:2/28/2015)... 28, 2015 1Heart Caregiver Services ... emerging brand at Houston Texas Franchise Expo South ... sending its executive delegates headed by Vice-President of ... and Training Randolph Clarito. , Franchise Expo South, ... last February 4-7 and featured Franchise brands of ...
(Date:2/27/2015)... 27, 2015 OnChip Devices , ... introduced miniature, wire bondable, silicon ESD (Electrostatic Discharge) protection ... The ESD88NP and ESD88PN ... sensitive LED and IC products. These Zeners exhibit ... All devices meet the requirements of IEC61000 and ...
Breaking Medicine News(10 mins):Health News:Friedman Dental Group Announces Their Updated Website 2Health News:Mercy Harvard Hospital Recognized as Leader in Stroke Care - Javon Bea 2Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 3Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 3
... a neurobiological side to it. A new study suggests ... ,David Erritzoe and his colleagues at Copenhagen University ... normal weight and 29 overweight people. They found that ... the neurotransmitter serotonin than those of normal weight, reported ...
... methods of treatment in Urogynaecology will be the focus ... on Urogynaecology and Reconstructive pelvic surgery, that begins here ... of a pelvic surgery, being conducted at Government Kasturba ... ,,Briefing reporters about the three-day conference, Dr ...
... emirate will start a health insurance policy next month which ... companies that fall under the Phase 1 category will be ... which will make the lowest paid the first to benefit ... of the General Authority for Health Services (GAHS) in Abu ...
... has come up in Kolkata to contain Diarrheal diseases in ... one of the best of its kind equipped with the ... Minister for Health & Family Welfare, Dr. Anbumani Ramadoss, will ... named the 'Diarrheal Research and Control Centre' (DRCC) in the ...
... to Dr. Alexis Carrel digestive wastes which become stagnant in our ... 1911 for his discovery that growing live tissue cells can be ... not removed for three days then the cells become weak and ... meal that one eats. ,Studies have shown that if ...
... NHS news it is said that the breast cancer drug Herceptin ... But this is not happy news to the grieving family of ... cancer. But NHS officials denied her the drug which led to ... ,By profession she was an advertising art director from Wimbledon, ...
Cached Medicine News:Health News:Health Minister Inaugurates Institute for Diarrhea Diseases 2
Auto Refkeratomoeter...
... Management System answers the day-to-day needs ... flexibility. From programming to data retrieval, ... management right where you want it. ... to help each patient become ambulatory ...
... can be customized with selectable performance parameters ... and therapies. The COLLEAGUE pumps allow ... used for both gravity and pump regulation, ... simple infusions to medication therapies requiring complex ...
ChildLab is a service of Children's Hospital, Columbus Ohio...
Medicine Products: